logo
Share SHARE
FONT-SIZE Plus   Neg

Verenium Completes Repurchase Of Senior Notes

Biotechnology company Verenium Corp. (VRNM) said Monday it has repurchased all its outstanding 5.5 percent convertible senior notes due 2027.

The tender offer period for the put option on the notes expired on March 30

All noteholders validly tendered their notes and the company repurchased the outstanding principal amount of $34.9 million.

Verenium paid $35.8 million in cash to its noteholders, including accrued and unpaid interest, for completing this repurchase.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sony announced Project Field, a new play way to bring card games to life, along with a host of smartphone games at an event in Japan, aiming to accelerate mobile drive. Project Field is a Japan-only card collection platform where actual physical cards will work with a smartphone app. The first title to be announced is based on Yo-kai Watch for mobile. There is no news about an international releas Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember.
comments powered by Disqus
Follow RTT